ERBB3 and colorectal carcinoma: In addition, we confirmed that HER-3high CRC cells can be efficiently targeted in vitro and in vivo by anti-HER-3/ADC EV20/MMAF, thus supporting the notion that the clinical development of such therapy may be promising.